Inluriyo (Imlunestrant)

Imlunestrant is a medicine used to treat a type of advanced breast cancer that has kept growing after hormone therapy. It works by blocking and breaking down the estrogen receptors that help the cancer grow. It's taken as a pill by mouth.

Brand names:Inluriyo
Medication

What people taking Inluriyo (Imlunestrant) report

Every report comes from a Lived member, sent anonymously.

Have you tried Inluriyo (Imlunestrant) for Breast Cancer?

NameHow it went

About Inluriyo (Imlunestrant)

What It's For

Imlunestrant, sold as Inluriyo, is a prescription hormone therapy pill for adults with advanced or metastatic breast cancer that is estrogen receptor-positive (ER-positive, meaning estrogen fuels its growth) and HER2-negative (without high levels of HER2, a protein that drives some breast cancers), and that has kept growing despite at least one earlier hormone therapy. It is approved only when the cancer carries a mutation in the ESR1 gene, which makes the estrogen receptor active even when estrogen levels are very low. That change often develops during treatment with aromatase inhibitors, pills that lower estrogen levels, such as letrozole or anastrozole, and it helps explain why those medicines can stop working. An FDA-authorized blood test that looks for tumor DNA circulating in the bloodstream, is needed to confirm the ESR1 mutation before treatment. Inluriyo can be used on its own or together with abemaciclib (Verzenio), a targeted pill that slows cancer cell division. In its main study, imlunestrant alone did not help people whose cancer lacked an ESR1 mutation.

How It Works

In ER-positive breast cancer, estrogen attaches to a receptor inside the cancer cell and switches on genes that drive the cell to grow and divide. Imlunestrant is a selective estrogen receptor degrader, or SERD. It binds to the estrogen receptor, blocks it and causes the cell to break the receptor down, so the growth signal is cut off at its source rather than by lowering estrogen in the body. This matters for ESR1-mutated cancers because the mutated receptor can signal without estrogen, which is why lowering estrogen alone stops working. Removing the receptor itself still works against these mutations in laboratory studies. Abemaciclib, when added, acts on a different step, the machinery a cell uses to divide, which is why the two are combined.

Dosage & Administration

Inluriyo comes as 200 mg tablets. The usual dose is 400 mg (two tablets) by mouth once a day, whether it is taken alone or with abemaciclib, and treatment continues as long as it is working and tolerated. Take it at about the same time each day on an empty stomach, at least 2 hours before eating or 1 hour after. Swallow the tablets whole; do not split, crush or chew them. If a dose is 6 or more hours late, or you vomit after taking it, skip that dose and take the next one the following day at the usual time rather than doubling up. The care team may lower the dose to 200 mg for side effects, for moderate or severe liver disease, or when another medicine raises imlunestrant levels. Abemaciclib has its own dosing schedule, usually twice a day.

Side Effects

Taken alone, imlunestrant was generally well tolerated in its main study, with few people stopping because of side effects. The most common effects people notice are muscle, joint or bone aches, tiredness, diarrhea, nausea, constipation and stomach pain. Routine blood tests may also show lower red blood cell, white blood cell or platelet counts, low calcium, higher liver enzymes and higher cholesterol or triglycerides, often without symptoms. Side effects are much more frequent when Inluriyo is taken with abemaciclib. Diarrhea affected most people on the combination, along with nausea, vomiting, tiredness, infections, lower blood counts and reduced appetite, and about half needed a pause in treatment. Diarrhea on the combination is best managed early, so contact the care team when it starts, and report fever or other signs of infection promptly, since low white cell counts make infections more serious.

Interactions & Warnings

Imlunestrant can harm a developing baby. People who could become pregnant should use effective birth control during treatment and for 1 week after the last dose, and men with a partner who could become pregnant should do the same. Tell the care team right away about a known or possible pregnancy. Do not breastfeed during treatment or for 1 week afterward. When abemaciclib is part of treatment, its longer timeframes apply to both birth control and breastfeeding: 3 weeks after the last dose. Imlunestrant may also reduce fertility in both women and men, which is worth raising before starting if future children matter. The body clears imlunestrant through a liver enzyme called CYP3A. Some medicines strongly block this enzyme, such as the antifungal itraconazole or the antibiotic clarithromycin, and can raise imlunestrant to levels that cause more side effects. Others strongly speed it up, such as the seizure medicine carbamazepine, the tuberculosis antibiotic rifampin or the herbal supplement St. John's wort, and can make it less effective. These combinations are best avoided, or the dose adjusted. Imlunestrant can also raise levels of some other medicines, so share a full list of prescriptions, over-the-counter products and supplements with the oncology team and pharmacist.

What to Expect

Imlunestrant is meant to control advanced breast cancer and slow its growth, not to cure it. In the main study of people with ESR1-mutated cancer, half of those taking imlunestrant alone went about 5.5 months without the cancer growing, compared with about 3.8 months on standard hormone therapy (fulvestrant injections or exemestane pills). In an exploratory analysis of a smaller group, adding abemaciclib roughly doubled that time, to about 11 months, though with more side effects. Responses vary widely, and whether imlunestrant helps people live longer was not yet known when it was approved. Treatment involves regular visits, blood tests that check blood counts, liver function, cholesterol and triglycerides, and periodic scans to see whether the cancer is shrinking, stable or growing. Treatment usually continues until scans show progression or side effects become too difficult, at which point the team discusses other options. Because it is a daily pill, most of the treatment happens at home.

Questions to Ask Your Doctor

  1. 1.What did my ESR1 test show, and how does that make imlunestrant a reasonable choice compared with other options?
  2. 2.Should I take imlunestrant alone or with abemaciclib, and how do the benefits and side effects compare for me?
  3. 3.How will we know if it is working, and how often will I have scans and blood tests?
  4. 4.Do any of my current medicines or supplements interact with imlunestrant?
  5. 5.What should I do if diarrhea, fever or other side effects start, and who should I call after hours?

Last reviewed • Oct 2026

Educational content, not medical advice.